BIRC5 and cancer: In both cancer cell-lines, KU174 demonstrated a dose-dependent reduction in Hsp (Hsc70 and Hsp27), HSF-1 and client proteins (survivin Akt, Her2, nestin, CXCR4 and caspase-3) whereas, a minimal effect was seen on these proteins in normal RPTEC cells (data not shown).